References
1: AkaRx Inc. Doptelet (avatrombopag) Product Monograph. Reference ID: NDA210238, 07/2024.
2: Amstutz U, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update. Clin Pharmacol Ther. 2018;103(2):210-216.
3: Bell GC, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and use of ondansetron and tropisetron. Clin Pharmacol Ther. 2017;102(2):213-218.
4: Birdwell KA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP3A5 Genotype and Tacrolimus Dosing. Clin Pharmacol Ther. 2015;98(1):19-24.
5: Bousman CA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6, CYP2C19, CYP2B6, SLC6A4, and HTR2A Genotypes and Serotonin Reuptake Inhibitor Antidepressants. Clin Pharmacol Ther. 2023;114(1):51-68.
6: Brown JT, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Cytochrome P450 (CYP)2D6 Genotype and Atomoxetine Therapy. Clin Pharmacol Ther. 2019;106(1):94-102.
7: Cooper-DeHoff RM, et al. The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1, ABCG2, and CYP2C9 genotypes and Statin-Associated Musculoskeletal Symptoms. Clin Pharmacol Ther. 2022;111(5):1007-1021.
8: Crews KR, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy. Clin Pharmacol Ther. 2021;110(4):888-896.
9: Desta Z, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy. Clin Pharmacol Ther. 2019;106(4):726-733.
10: Dutch Pharmacogenetics Working Group. Dutch Pharmacogenetics Working Group Guidelines May 2023. https://www.pharmgkb.org/pgkbPublications
11: Gammal RS, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for UGT1A1 and Atazanavir Prescribing. Clin Pharmacol Ther. 2016;99(4):363-369.
12: Gammal RS, et al. Expanded Clinical Pharmacogenetics Implementation Consortium Guideline for Medication Use in the Context of G6PD Genotype. Clin Pharmacol Ther. 2023;113(5): 973-985.
13: Goetz MP, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2D6 and Tamoxifen Therapy. Clin Pharmacol Ther. 2018;103(5):770-777.
14: Gonsalves SG, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for the Use of Potent Volatile Anesthetic Agents and Succinylcholine in the Context of RYR1 or CACNA1S Genotypes. Clin Pharmacol Ther. 2019;105(6):13381344.
15: Harmony Biosciences, LLC. Wakix (pitolisant) Product Monograph. Reference ID: NDA211150, 12/2022.
16: Hicks JK, et al. Clinical pharmacogenetics implementation consortium guideline (CPIC) for CYP2D6 and CYP2C19 genotypes and dosing of tricyclic antidepressants: 2016 update. Clin Pharmacol Ther. 2017;102(1):37-44.
17: Johnson JA, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Pharmacogenetics-Guided Warfarin Dosing: 2017 Update. Clin Pharmacol Ther. 2017;102(3):397-404.
18: Karnes JH, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C9 and HLA-B Genotypes and Phenytoin Dosing: 2020 Update. Clin Pharmacol Ther. 2021;109(2):302-309.
19: Lee CR, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2C19 Genotype and Clopidogrel Therapy: 2022 Update. Clin Pharmacol Ther. 2022;112(5):959-967.
20: Lima JJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2C19 and Proton Pump Inhibitor Dosing. Clin Pharmacol Ther. 2021;109(6):1417-1423.
21: Lundbeck Pharmaceuticals LLC. Onfi (clobazam) Product Monograph. Reference ID: NDA202067/ NDA203993, 03/2024.
22: Martin MA, et al. Clinical pharmacogenetics implementation consortium guidelines for HLA-B genotype and abacavir dosing. Clin Pharmacol Ther. 2012;91(4):734-738.
23: McDermott JH, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for the Use of Aminoglycosides Based on MT-RNR1 Genotype. Clin Pharmacol Ther. 2022;111(2):366-372.
24: Moriyama B, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy. Clin Pharmacol Ther. 2017;102(1):45-51.
25: Muir AJ, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens. Clin Pharmacol Ther. 2014;95(2):141-146.
26: Novartis Pharmaceuticals Corporation. Promacta (eltrombopag) Product Monograph. Reference ID: 4599937, 04/2020.
27: Pfizer Laboratories Div Pfizer Inc. Cibinqo (abrocitinib) Product Monograph. Reference ID: NDA213871, 12/2023.
28: Phillips EJ, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for HLA Genotype and Use of Carbamazepine and Oxcarbazepine: 2017 Update. Clin Pharmacol Ther. 2018;103(4):574-581.
29: Relling MV, et al. Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on TPMT and NUDT15 Genotypes: 2018 Update. Clin Pharmacol Ther. 2019;105(5):1095-1105.
30: Saito Y, et al. Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for human leukocyte antigen B (HLA-B) genotype and allopurinol dosing: 2015 update. Clin Pharmacol Ther. 2016;99(1):36-37.
31: Shionogi Inc. Mupleta (lusutrombopag) Product Monograph. Reference ID: NDA210923, 10/2020.
32: The Clinical Pharmacogenetics Implementation Consortium. CPIC Guideline for Thiopurines and TPMT and NUDT15 – Updates since publication Mar 2024. https://cpicpgx.org/guidelines/guideline-for-thiopurines-and-tpmt/
33: Theken KN, et al. Clinical Pharmacogenetics Implementation Consortium Guideline (CPIC) for CYP2C9 and Nonsteroidal AntiInflammatory Drugs. Clin Pharmacol Ther. 2020;108(2):191-200.
34: US Food and Drug Administration. Table of Pharmacogenetic Associations: Section 1: Pharmacogenetic associations for which the data support therapeutic management recommendations. Section 2: Pharmacogenetic associations for which the data indicate a potential impact on safety or response. Section 3: Pharmacogenetic associations for which the data demonstrate a potential impact on pharmacokinetic properties only. 2022. fda.gov/medical-devices/precision-medicine/table-pharmacogenetic-associations
Menu
Legal Disclaimer: “The information provided on this website is for general informational purposes only and is not intended to be a substitute for professional medical advice, diagnosis, or treatment. GenXys does not endorse or promote any specific tests, physicians, products, procedures, opinions, or other information mentioned herein. Always seek the advice of your physician or other qualified healthcare provider with any questions you may have regarding a medical condition. Use of this website is subject to the terms and conditions set forth in our Privacy Policy and Terms of Use. GenXys operates in accordance with the regulatory requirements of Canada but may not meet the regulations of other jurisdictions. By accessing and using this website, you agree to comply with all applicable local laws and regulations. If you do not agree, please do not use this site. Privacy and Data Disclaimer: “GenXys is committed to protecting the privacy and security of your personal information. We adhere to stringent data protection regulations in Canada and globally to ensure that your data is handled responsibly and securely. Any personal or health-related information collected through this website is used solely for the purpose of providing and improving our services, and it will not be shared with third parties without your consent, except as required by law. By using this site, you agree to our Privacy Policy, which outlines how we collect, use, and protect your information. For more details, please review our Privacy Policy and Terms of Use.”